硒联合化疗治疗妇科癌症的I期试验
该I期试验在45例初治妇科癌症患者中评估静脉亚硒酸联合卡铂/紫杉醇的最大耐受剂量、安全性和对卡铂药代动力学的影响。硒剂量从50 μg至5000 μg递增,未达到最大耐受剂量,硒未改变卡铂药代动力学,3/4级毒性以中性粒细胞减少为主(66.7%)。作者建议II期试验评估5000 μg元素硒剂量。
要点
- 45例初治妇科癌症患者接受亚硒酸联合卡铂/紫杉醇,硒剂量50-5000 μg,未达到最大耐受剂量。
- 3/4级毒性包括中性粒细胞减少66.7%、疼痛20.0%、感染13.3%、神经毒性11.1%、肺部不良反应11.1%。
- 硒未改变卡铂药代动力学,作者建议II期试验评估5000 μg元素硒剂量。
核心结论
- 总体而言,在卡铂/紫杉醇化疗中加入硒是安全的且耐受性良好,并且不改变卡铂药代动力学。
- 作者建议将5000 μg元素硒(以亚硒酸形式给药)作为II期试验中评估的剂量。
研究设计与样本
- I期试验,采用标准3+3剂量递增设计,在标准化疗基础上加入硒。
- 纳入45例初治妇科恶性肿瘤患者,共接受291个治疗周期。
- 患者第1天静脉接受亚硒酸,第3天静脉接受卡铂和紫杉醇。
- 硒以亚硒酸形式给予9个队列患者,剂量范围为50 μg至5000 μg。
- 分析血浆硒浓度和血浆超滤液中卡铂浓度。
主要发现
- 3/4级毒性包括中性粒细胞减少(66.7%)、发热性中性粒细胞减少(2.2%)、疼痛(20.0%)、感染(13.3%)、神经毒性(11.1%)和肺部不良反应(11.1%)。
- 未达到硒的最大耐受剂量。
- 硒对卡铂药代动力学无影响。
- 相关性研究显示,治疗后RAD51AP1(一种参与DNA修复的蛋白)在癌细胞系和患者肿瘤中均下调。
临床怎么用
- 作者建议将5000 μg元素硒(以亚硒酸形式给药)作为II期试验中评估的剂量。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Preclinical studies performed in our laboratory have shown that high-dose selenium inhibits the development of carboplatin drug resistance in an ovarian cancer mouse xenograft model. Based on these data, as well as the potential serious toxicities of supranutritional doses of selenium, a phase I trial of a combination of selenium/carboplatin/paclitaxel was designed to determine the maximum tolerated dose, safety, and effects of selenium on carboplatin pharmacokinetics in the treatment of chemo-naive women with gynecologic cancers. Correlative studies were performed to identify gene targets of selenium. METHODS: Chemo-naïve patients with gynecologic malignancy received selenious acid IV on day 1 followed by carboplatin IV and paclitaxel IV on day 3. A standard 3 + 3 dose-escalating design was used for addition of selenium to standard dose chemotherapy. Concentrations of selenium in plasma and carboplatin in plasma ultrafiltrate were analyzed. RESULTS: Forty-five patients were enrolled and 291 treatment cycles were administered. Selenium was administered as selenious acid to 9 cohorts of patients with selenium doses ranging from 50 μg to 5000 μg. Grade 3/4 toxicities included neutropenia (66.7%), febrile neutropenia (2.2%), pain (20.0%), infection (13.3%), neurologic (11.1%), and pulmonary adverse effects (11.1%). The maximum tolerated dose of selenium was not reached. Selenium had no effect on carboplatin pharmacokinetics. Correlative studies showed post-treatment downregulation of RAD51AP1, a protein involved in DNA repair, in both cancer cell lines and patient tumors. CONCLUSION: Overall, the addition of selenium to carboplatin/paclitaxel chemotherapy is safe and well tolerated, and does not alter carboplatin pharmacokinetics. A 5000 μg dose of elemental selenium as selenious acid is suggested as the dose to be evaluated in a phase II trial.
引用
- Song M, Kumaran MN, Gounder M, et al. Phase I trial of selenium plus chemotherapy in gynecologic cancers. Gynecol Oncol. 2018. PMID: 30068487. doi:10.1016/j.ygyno.2018.07.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。